Scarica l'app Stockscreener
70.49
2.76%
-2.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com India
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells 3,162 Shares of Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - Investing.com South Africa
Ani pharmaceuticals SVP Rowland sells $357k in stock - Investing.com India
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
ANI Pharmaceuticals, Inc. $ANIP Stock Position Reduced by Kennedy Capital Management LLC - MarketBeat
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - simplywall.st
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - MarketBeat
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) CEO stock withheld to cover taxes - Stock Titan
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Insider Moves At ANI Pharmaceuticals Contrast With Valuation Gap And Pullback - Sahm
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Insider Trades And Rare Disease Growth Shape ANI Pharmaceuticals Valuation - finance.yahoo.com
What ANI Pharmaceuticals (ANIP)'s Strong Q4 Turnaround and Cautious 2026 Outlook Means For Shareholders - Yahoo Finance
Stephen P Carey At ANI Pharmaceuticals Decides to Exercises Options Worth $86K - Benzinga
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best - Yahoo Finance
Stephen Carey Sells 7,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) CFO sells shares after option exercise - Stock Titan
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView
Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ori Gutwerg Sells 2,060 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (ANIP) rare disease head sells 417 shares under 10b5-1 plan - Stock Titan
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Director at ANI Pharmaceuticals (ANIP) sells 6,000 shares - Stock Titan
SVP & CFO At ANI Pharmaceuticals Buys $1.72M of StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
833K Reasons To Be Bullish On ANI Pharmaceuticals StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
SVP Of ANI Pharmaceuticals Makes $1.00M BuyANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
SVP Of ANI Pharmaceuticals Purchased $464K In StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
ANI Pharmaceuticals (ANIP) Stock Analysis: A Compelling 47% Upside Potential Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. - MarketBeat
ANI Pharmaceuticals at Raymond James Conference: Rare Disease Focus By Investing.com - Investing.com Canada
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors - TipRanks
ANI Pharmaceuticals projects >$1B revenue in 2026, guides $275–$290M adjusted EBITDA - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance - MarketBeat
ANI Pharmaceuticals : Corporate Presentation March 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ: ANIP) guides to over $1B in 2026 revenue - Stock Titan
Guggenheim Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
ANI Pharmaceuticals (ANIP) SVP receives stock award, withholds shares for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) exec logs stock award and tax share disposal - Stock Titan
ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition - Stock Titan
ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4 - Stock Titan
ANI Pharmaceuticals (ANIP) SVP reports stock award, tax withholding and LLC-held shares - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding - Stock Titan
Restricted stock grant for ANI Pharmaceuticals (ANIP) general counsel - Stock Titan
ANI Pharmaceuticals (ANIP) CFO awarded restricted stock and has shares withheld for taxes - Stock Titan
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
ANI Pharmaceuticals Reshapes Portfolio With Alimera Deal And Rare Disease Push - Yahoo Finance
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):